Illumina Inc (ILMN) FinancialsILMNIllumina Inc

Illumina Inc (ILMN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables, accounting for 73.5% of total sales, equivalent to $852.00M. Other significant revenue streams include Services and Other revenue and Instruments. Understanding this composition is critical for investors evaluating how ILMN navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Illumina Inc maintains a gross margin of 66.44%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 17.69%, while the net margin is 17.86%. These profitability ratios, combined with a Return on Equity (ROE) of 32.34%, provide a clear picture of how effectively ILMN converts its operational activities into shareholder value.

In the context of the broader market, ILMN competes directly with industry leaders such as IDXX and WAT. With a market capitalization of $42.71B, it holds a significant position in the sector. When comparing efficiency, ILMN's gross margin of 66.44% stands against IDXX's 64.04% and WAT's 29.79%. Such benchmarking helps identify whether Illumina Inc is trading at a premium or discount relative to its financial performance.

Illumina has shown strong revenue growth, with total revenue reaching $1.159 billion in Q4 2025, and a gross margin of 66.44% in Q2 2026. However, the net income margin has fluctuated, with a recent net margin of 17.86% in Q2 2026, which may indicate variability in profitability.